Partnership OpportunitiesManagement is in discussions with potential partners to fund continued development of PrimeC, which could provide additional financial support.

Regulatory ApprovalCanadian regulatory authorities may be less strict on conditional approval requirements, increasing the possibility of success for PrimeC.

Bears Say

Dilution RiskAccessing the full $30M from the Equity Purchase Agreement would be significantly dilutive given the current stock price.

Financial ConstraintsCapital constraints, including 'baby shelf' limitations, make it difficult to raise sufficient capital to fully finance the Phase 3 trial.

Regulatory ChallengesShares are downgraded to Hold due to the unlikelihood of pursuing an Accelerated Approval pathway in the U.S. for PrimeC.

---

Financials

Annual

Income Statement >

Ownership Overview

26.88%

Insiders

0.05% Mutual Funds

0.52% Other Institutional Investors

72.55% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Detailed Risk Analysis >

NRSN FAQ

What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?

Neurosense Therapeutics Ltd. lowest stock price was $0.51 and its highest was $2.33 in the past 12 months.

What is Neurosense Therapeutics Ltd.’s market cap?

Neurosense Therapeutics Ltd.’s market cap is $25.55M.

When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?

Neurosense Therapeutics Ltd.’s upcoming earnings report date is Mar 19, 2025 which is in 47 days.

How were Neurosense Therapeutics Ltd.’s earnings last quarter?

Neurosense Therapeutics Ltd. released its earnings results on Dec 18, 2024. The company reported -$0.11 earnings per share for the quarter, the consensus estimate of -$0.11 by $0.

Is Neurosense Therapeutics Ltd. overvalued?

According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neurosense Therapeutics Ltd. pay dividends?

Neurosense Therapeutics Ltd. does not currently pay dividends.

What is Neurosense Therapeutics Ltd.’s EPS estimate?

Neurosense Therapeutics Ltd.’s EPS estimate is -0.08.

How many shares outstanding does Neurosense Therapeutics Ltd. have?

Neurosense Therapeutics Ltd. has 23,228,941 shares outstanding.

What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?

Neurosense Therapeutics Ltd. reported an EPS of -$0.11 in its last earnings report, expectations of -$0.11. Following the earnings report the stock price went up 4.587%.

Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?

Currently, no hedge funds are holding shares in NRSN

---

Company Description

Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

---